Tyra announces initial data from Phase II SURF302 trial of dabogratinib
In the trial, dabogratinib’s safety profile was evaluated in 60mg and 50mg once-daily cohorts, each with 22 participants.
Analysis
View MoreAPIs to the rescue?
Oral bioavailability remains one of the biggest challenges in drug development, particularly for small-molecule APIs with poor solubility or permeability. Liam Critchley explores how pharmaceutical companies are using integrated formulation...
AI now: What QbD and PAT missed
Cool heads, smart chains
Sustainability vs suitability
Integrating sustainability compliance